Varghese Jr. becomes just the eighth Editor-in-Chief during the 119-year history of the JACS, where he will be tasked with driving innovation and inspiring the next generation of surgical pioneers.
Sorry, your request to load the app is timing out. Please check your internet connection and refresh the page. If the issue continues, try in…
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier…
One year after the Centers for Medicare & Medicaid Services made the decision to pay for patient navigation services, data from early adopters show that…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The NCI Cancer Center Support Grant requires community outreach and engagement, but the design and implementation of COE programs, as well as staff training, are…
David S. Miller, MD, discusses key efficacy, safety, and quality-adjusted survival data with selinexor in TP53 wild-type endometrial cancer.
A panel discussed on RCC and the differentiation in the identification and treatment of clear and non-clear cell RCC.
IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.
A biologics license application was submitted to the FDA seeking the approval of RP1 plus nivolumab for patients with PD-1 inhibitor–exposed melanoma.
The NCI Cancer Research Data Commons has launched the Clinical and Translational Data Commons, a dedicated resource for NCI-funded clinical and translational data. Learn more…
